AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Amgen Inc. (AMGN): Analyst Consensus and Price Target
ByAinvest
Tuesday, Sep 16, 2025 3:04 pm ET1min read
Amgen Inc. (AMGN) reported Q2 2025 earnings with total revenues increasing 9% to $9.2 billion and GAAP EPS rising 92% to $2.65. Analysts maintain a Moderate Buy consensus with a median price target of $276.39, implying a 12.16% upside from current levels.
Amgen Inc. (AMGN) reported its Q2 2025 earnings on September 12, 2025, with total revenues increasing 9% to $9.2 billion. The company's GAAP EPS rose by 92% to $2.65, reflecting robust financial performance. Analysts maintain a Moderate Buy consensus with a median price target of $276.39, indicating a 12.16% upside from current levels [1].The earnings report highlighted Amgen's strong performance across its various therapeutic areas. The company's revenue growth was driven by increased sales of its key products, including biosimilars and biologic therapies. The significant improvement in GAAP EPS underscores the company's operational efficiency and effective cost management.
Amgen's stock has shown resilience despite the broader market volatility. The company's strong earnings report has been well-received by investors, with analysts maintaining a bullish outlook. The median price target suggests that Amgen's stock has the potential to appreciate further, driven by its solid financial performance and the expectation of future growth.
In addition to its Q2 results, Amgen has been actively expanding its pipeline and exploring strategic partnerships to bolster its position in the biopharmaceutical industry. The company's focus on innovation and growth strategies is likely to continue supporting its financial performance in the coming quarters.
Overall, Amgen's Q2 2025 earnings report demonstrates the company's strong financial health and growth potential. The company's robust performance and analysts' positive outlook suggest that Amgen is well-positioned to continue delivering value to shareholders.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet